These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

551 related articles for article (PubMed ID: 30745819)

  • 1. Role of Nutrition in the Pathogenesis and Prevention of Non-alcoholic Fatty Liver Disease: Recent Updates.
    Ullah R; Rauf N; Nabi G; Ullah H; Shen Y; Zhou YD; Fu J
    Int J Biol Sci; 2019; 15(2):265-276. PubMed ID: 30745819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Free fatty acids, not triglycerides, are associated with non-alcoholic liver injury progression in high fat diet induced obese rats.
    Liu J; Han L; Zhu L; Yu Y
    Lipids Health Dis; 2016 Feb; 15():27. PubMed ID: 26868515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fatty acids promote fatty liver disease via the dysregulation of 3-mercaptopyruvate sulfurtransferase/hydrogen sulfide pathway.
    Li M; Xu C; Shi J; Ding J; Wan X; Chen D; Gao J; Li C; Zhang J; Lin Y; Tu Z; Kong X; Li Y; Yu C
    Gut; 2018 Dec; 67(12):2169-2180. PubMed ID: 28877979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular mechanisms of nonalcoholic fatty liver disease: Potential role for 12-lipoxygenase.
    Samala N; Tersey SA; Chalasani N; Anderson RM; Mirmira RG
    J Diabetes Complications; 2017 Nov; 31(11):1630-1637. PubMed ID: 28886991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of Innate Immune Signaling in Non-Alcoholic Fatty Liver Disease.
    Cai J; Zhang XJ; Li H
    Trends Endocrinol Metab; 2018 Oct; 29(10):712-722. PubMed ID: 30131212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adrenic acid as an inflammation enhancer in non-alcoholic fatty liver disease.
    Horas H Nababan S; Nishiumi S; Kawano Y; Kobayashi T; Yoshida M; Azuma T
    Arch Biochem Biophys; 2017 Jun; 623-624():64-75. PubMed ID: 28456640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. From sugar to liver fat and public health: systems biology driven studies in understanding non-alcoholic fatty liver disease pathogenesis.
    Moore JB
    Proc Nutr Soc; 2019 Aug; 78(3):290-304. PubMed ID: 30924429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Glucagon-Like Peptide-1 Analogue Liraglutide Inhibits Oxidative Stress and Inflammatory Response in the Liver of Rats with Diet-Induced Non-alcoholic Fatty Liver Disease.
    Gao H; Zeng Z; Zhang H; Zhou X; Guan L; Deng W; Xu L
    Biol Pharm Bull; 2015; 38(5):694-702. PubMed ID: 25947915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Omega-3 fatty acids and non-alcoholic fatty liver disease: Evidence of efficacy and mechanism of action.
    Scorletti E; Byrne CD
    Mol Aspects Med; 2018 Dec; 64():135-146. PubMed ID: 29544992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-Alcoholic Fatty Liver Disease.
    Engin A
    Adv Exp Med Biol; 2017; 960():443-467. PubMed ID: 28585211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LPS-induced TNF-α factor mediates pro-inflammatory and pro-fibrogenic pattern in non-alcoholic fatty liver disease.
    Ceccarelli S; Panera N; Mina M; Gnani D; De Stefanis C; Crudele A; Rychlicki C; Petrini S; Bruscalupi G; Agostinelli L; Stronati L; Cucchiara S; Musso G; Furlanello C; Svegliati-Baroni G; Nobili V; Alisi A
    Oncotarget; 2015 Dec; 6(39):41434-52. PubMed ID: 26573228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interplay between Oxidative Stress and Metabolic Derangements in Non-Alcoholic Fatty Liver Disease: The Role of Selenoprotein P.
    Caviglia GP; Rosso C; Armandi A; Gaggini M; Carli F; Abate ML; Olivero A; Ribaldone DG; Saracco GM; Gastaldelli A; Bugianesi E
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33266488
    [No Abstract]   [Full Text] [Related]  

  • 13. Non-alcoholic fatty liver disease and dyslipidemia: An update.
    Katsiki N; Mikhailidis DP; Mantzoros CS
    Metabolism; 2016 Aug; 65(8):1109-23. PubMed ID: 27237577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemokine ligand 2 and paraoxonase-1 in non-alcoholic fatty liver disease: The search for alternative causative factors.
    Camps J; Joven J
    World J Gastroenterol; 2015 Mar; 21(10):2875-82. PubMed ID: 25780284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Innate immune regulatory networks in hepatic lipid metabolism.
    Bai L; Li H
    J Mol Med (Berl); 2019 May; 97(5):593-604. PubMed ID: 30891617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p53 as a double-edged sword in the progression of non-alcoholic fatty liver disease.
    Yan Z; Miao X; Zhang B; Xie J
    Life Sci; 2018 Dec; 215():64-72. PubMed ID: 30473026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteomic and genomic studies of non-alcoholic fatty liver disease--clues in the pathogenesis.
    Lim JW; Dillon J; Miller M
    World J Gastroenterol; 2014 Jul; 20(26):8325-40. PubMed ID: 25024592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pomegranate juice prevents development of non-alcoholic fatty liver disease in rats by attenuating oxidative stress and inflammation.
    Noori M; Jafari B; Hekmatdoost A
    J Sci Food Agric; 2017 Jun; 97(8):2327-2332. PubMed ID: 27717115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A concise review of non-alcoholic fatty liver disease.
    Than NN; Newsome PN
    Atherosclerosis; 2015 Mar; 239(1):192-202. PubMed ID: 25617860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of beneficial effects of exercise training on non-alcoholic fatty liver disease (NAFLD): Roles of oxidative stress and inflammation.
    Farzanegi P; Dana A; Ebrahimpoor Z; Asadi M; Azarbayjani MA
    Eur J Sport Sci; 2019 Aug; 19(7):994-1003. PubMed ID: 30732555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.